Castellanos CJ, Pinto SME, Carrero SH, Torres GCA, Chacón R

Language: Spanish
References: 21
Page: 52-56
PDF size: 152.97 Kb.

ABSTRACT

Postoperative nausea and vomiting (PONV) in laparoscopic cholecystectomy surgery is common. The use of ondansetron and dexamethasone (GOD) and palonosetron (GP) is very prevalent. Objective: To compare the effectiveness in the control of the PONV. Material and methods: We conducted a comparative study of two retrospective cohorts of 62 patients each with elective cholecystectomy surgery; one with GOD prophylaxis and another with GP. The risk of PONV was assessed by the Apfel scale. The PONVs were studied in the 24 hours post-recovery of the anesthesia. Results: There were no differences regarding gender, pre-anesthetic assessment (ASA) and risk of PONV between the groups. 12.9% (8/62) of the patients in the GOD group had nausea against those in the GP group (p = 0.003). No patient presented post-operative vomiting (p = 1.00). In the GOD group, six patients required pharmacological rescue (9.6%) compared to none in the GP (p = 0.014). There were no side effects in either group. Conclusion: The use of palonosetron evidenced better control of nausea, but both prophylactic strategies controlled post-operative vomiting.

REFERENCES

1. Turkistani A, Abdullah K, Manaa E, Delvi B, Khairy G, Abdulghani B et al. Effect of fluid preloading on postoperative nausea and vomiting following laparoscopic cholecystectomy. Saudi J Anaesth. 2009; 3 (2): 48-52.

2. Hill RP, Lubarsky DA, Phillips-Bute B, Fortney JT, Creed MR, Glass PS et al. Cost-effectiveness of prophylactic antiemetic therapy with ondansetron, droperidol, or placebo. Anesthesiology. 2000; 92 (4): 958-967.

3. Tramèr MR. A rational approach to the control of postoperative nausea and vomiting: evidence from systematic reviews. Part II. Recommendations for prevention and treatment, and research agenda. Acta Anaesthesiol Scand. 2001; 45 (1): 14-19.

4. Gan TJ, Diemunsch P, Habib AS, Kovac A, Kranke P, Meyer TA et al. Consensus guidelines for the management of postoperative nausea and vomiting. Anesth Analg. 2014; 118 (1): 85-113.

5. Apfel CC, Laara E, Koivuranta M, Greim CA, Roewer N. A simplified risk score for predicting postoperative nausea and vomiting: conclusions from cross-validations between two centers. Anesthesiology. 1999; 91 (3): 693-700.

6. Gómez-Arnau JI, Aguilar JL, Bovaira P, Bustos F, de Andrés J, de la Pinta JC, et al. Recomendaciones de prevención y tratamiento de las náuseas y vómitos postoperatorios y/o asociados a las infusiones de opioides. Rev Esp Anestesiol Reanim. 2010; 57 (8): 508-524.

7. Arslan M, Ciçek R, Kalender HU, Yilmaz H. Preventing postoperative nausea and vomiting after laparoscopic cholecystectomy: a prospective, randomized, double-blind study. Curr Ther Res Clin Exp. 2011; 72 (1): 1-12.

8. Lagos AC, Quezada ES. Profilaxis y tratamiento de las náuseas y vómito postoperatorios. Rev Chil Anest. 2009; 38 (1): 24-33.

9. Scholz J. Essential drugs in anesthetic practice. Antiemetics. Anesthetic pharmacology. 2nd. United Kingdom: Cambridge University Press; 2011. pp. 855-873.

10. Thompson AJ, Lummis SC. The 5-HT3 receptor as a therapeutic target. Expert Opin Ther Targets. 2007; 11 (4): 527-540.

11. Carvalho Braga EL, Figueiredo NV, Barrucand L, Cavalcanti IL. Use of palonosetron and ondansetron in the prophylaxis of postoperative nausea and vomiting in women 60 years of age or older undergoing laparoscopic cholecystectomy: A randomised double-blind study. Eur J Anaesthesiol. 2019; 36 (3): 241-242. doi: 10.1097/EJA.0000000000000932.

12. Niesler B, Walstab J, Combrink S, Möller D, Kapeller J, Rietdorf J et al. Characterization of the novel human serotonin receptor subunits 5-HT3C,5-HT3D, and 5-HT3E. Mol Pharmacol. 2007; 72 (1): 8-17.

13. Henzi I, Walder B, Tramer MR. Dexamethasone for the prevention of postoperative nausea and vomiting: a quantitative systematic review. Anesth Analg. 2000; 90 (1): 186-194.

14. Rojas C, Stathis M, Thomas AG, Massuda EB, Alt J, Zhang J et al. Palonosetron exhibits unique molecular interactions with the 5-HT3 receptor. Anesth Analg. 2008; 107 (2): 469-478.

15. Wallenborn J, Kranke P. Palonosetron hydrochloride in the prevention and treatment of postoperative nausea and vomiting. Clinical Medicine Insights: Therapeutics. 2010; 2: 387-399.

16. Rojas C, Thomas AG, Alt J, Stathis M, Zhang J, Rubenstein EB et al. Palonosetron triggers 5-HT(3) receptor internalization and causes prolonged inhibition of receptor function. Eur J Pharmacol. 2010; 626 (2-3): 193-199.

17. Kovac AL, Eberhart L, Kotarski J, Clerici G, Apfel C; Palonosetron 04-07 Study Group. A randomized, double-blind study to evaluate the efficacy and safety of three different doses of palonosetron versus placebo in preventing postoperative nausea and vomiting over a 72-hour period. Anesth Analg. 2008; 107 (2): 439-444.

18. Pleuvry B. Physiology and pharmacology of nausea and vomiting. Anaesth Intens Care Med. 2006; 7 (12): 473-477.

19. Park SK, Cho EJ. A randomized, double-blind trial of palonosetron compared with ondansetron in preventing postoperative nausea and vomiting after gynaecological laparoscopic surgery. J Int Med Res. 2011; 39 (2): 399-407.

20. Xiong C, Liu G, Ma R, Xue J, Wu A. Efficacy of palonosetron for preventing postoperative nausea and vomiting: a systematic review and meta-analysis. Can J Anaesth. 2015; 62 (12): 1268-1278.

21. Laha B, Hazra A, Mallick S. Evaluation of antiemetic effect of intravenous palonosetron versus intravenous ondansetron in laparoscopic cholecystectomy: a randomized controlled trial. Indian J Pharmacol. 2013; 45 (1): 24-29.